Excess risk for contralateral breast cancer in CHEK2*1100delC germline mutation carriers.
We detected a significant excess risk for CHEK2*1100delC mutation carriers to develop a contralateral breast tumor, OR = 6.5 (95% CI 1.5-28.8, p = 0.005). The highest percentage of mutation carriers was detected among those bilateral breast cancer patients who had received radiation treatment for their first breast tumor. These results warrant prolonged medical surveillance and may indicate a clinically important interaction between CHEK2 heterozygosity and radiation in the development of contralateral breast cancer.
Broeks
Annegien
A
Division of Experimental Therapy, The Netherlands Cancer Institute, Amsterdam.
de Witte
Lot
L
Nooijen
Anke
A
Huseinovic
Angelina
A
Klijn
Jan G M
JG
van Leeuwen
Flora E
FE
Russell
Nicola S
NS
van't Veer
Laura J
LJ
D000328:Adult; D001943:Breast Neoplasms / Q000453:epidemiology* / Q000209:etiology / Q000235:genetics*; D064447:Checkpoint Kinase 2; D005260:Female; D020022:Genetic Predisposition to Disease; D018095:Germ-Line Mutation; D006579:Heterozygote; D006801:Humans; D008875:Middle Aged; D009426:Netherlands / Q000453:epidemiology; D017346:Protein Serine-Threonine Kinases / Q000235:genetics*
D064447:Checkpoint Kinase 2; C578634:CHEK2 protein, human; D017346:Protein Serine-Threonine Kinases